奥美拉唑在不同CYP2C19基因型幽门螺旋杆菌感染胃溃疡患者体内的药代动力学及药效学观察

发布时间：2018-04-21 04:49

  本文选题：CYPC基因型 + 奥美拉唑　； 参考：《山东医药》2015年19期

【摘要】：目的观察奥美拉唑在不同CYP2C19基因型幽门螺旋杆菌感染胃溃疡患者体内的药代动力学及药效学。方法幽门螺旋杆菌感染的胃溃疡患者100例,根据CYP2C19主要基因型将其分为CYP2C19*1型组和CYP2C19*2型组各50例。两组患者均接受奥美拉唑治疗,比较两组奥美拉唑药时曲线下面积(AUC)、药物半衰期(T1/2)、药—时曲线的最高点称峰浓度(Cmax)和血浆药物达峰时间(Tmax)、抑酸起效时间(达到p H≥4所需时间)、抑酸持续时间(p H≥4持续时间)、幽门螺旋杆菌根治率。结果 CYP2C19*1型组、CYP2C19*2型组AUC分别为(1 059.8±159.9)、(1 251.1±235.9)ng/(m L·h),Cmax分别为(300.5±25.9)、(263.7±33.5)ng/m L,Tmax分别为(2.7±0.60)、(2.3±0.3)h,T1/2分别为(1.7±0.4)、(2.4±0.7)h,抑酸起效时间分别为(126.4±64.4)、(98.5±59.9)min,抑酸持续时间分别为(258.8±88.9)、(315.3±75.8)min,幽门螺旋杆菌根除率分别为70.0%、94.0%,两组比较,P均0.05。结论较CYP2C19*1基因型,奥美拉唑在CYP2C19*2基因型幽门螺旋杆菌感染胃溃疡患者体内代谢快,有效时间长,幽门螺旋杆菌根除率高。
[Abstract]:Objective to observe the pharmacokinetics and pharmacodynamics of omeprazole in patients with gastric ulcer infected by Helicobacter pylori with different CYP2C19 genotypes. Methods 100 patients with gastric ulcer infected by Helicobacter pylori were divided into CYP2C19*1 type group and CYP2C19*2 type group according to their main genotypes of CYP2C19. Both groups were treated with omeprazole. The area under the time curve of omeprazole was compared between the two groups, the half life of the drug was T1 / 2, and the peak concentration of Cmaxwas at the highest point of the drug-hour curve, and the peak time of plasma drug reaching the peak was Tmax1, and the time of anti-acid effect (the time needed to reach pH 鈮，

本文编号：1780996